

## Indoco's domestic business outperforms the industry growth rates

January 29, 2013

January 29, 2013, Mumbai: Indoco Remedies Limited, a pharmaceutical company with global presence, recorded revenues at ₹1502.6 million during the third quarter of FY 2012-13 as compared to Rs.1417.5 million over the same quarter last year. Company's Domestic formulation business registered a growth of 11% as against Indian Pharma Market (IPM) growth of 9.1% during the quarter. The un-audited results for the third quarter of the financial year 2012-13 were announced by the Board of Directors of Indoco Remedies Limited at their meeting held in Mumbai on January 29, 2013.

Commenting on the performance, Mr. Suresh G. Kare, Executive Chairman said, "The Indian Pharma Market witnessed some slow down during the last quarter but is expected to rebound back in the coming quarters. Indoco's domestic business has performed better than industry and our strategies have paved well for growth in the coming quarters as well. On the International Business front, the growth during the quarter was marginal due to slowdown in emerging market tender business but we envisage to close the year with better numbers."

### **HIGHLIGHTS:**

#### **For Third Quarter ended December 2012 of FY 2012-13**

**Net Revenues at Rs.1502.6 million**

**EBIDTA at Rs.225.0 million**

**Profit After Tax at Rs.73.8 million**

**EPS at Rs.0.80**

**(Face value of Rs.2/- per share after split & bonus)**

For Nine Months ended December 2012 of FY 2012-13

**Net Revenues at Rs.4659.5 million**

**EBIDTA at Rs.777.6 million**

**Profit After Tax at Rs.298.1 million**

**EPS at Rs.3.23**

**(Face value of Rs.2/- per share after split & bonus)**